Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.
Campylobacter abortion in sheep:
a study of strain types and vaccine protection.

A thesis presented in fulfilment of the requirements for the degree of
Doctor of Philosophy in Veterinary Pathology

at Massey University, Palmerston North, New Zealand.

Sally Anne Mannering
2003
Abstract

The bacteria *Campylobacter fetus* subsp. *fetus* and *C. jejuni* are important causes of abortion in sheep, and the majority of *Campylobacter* sheep abortion in New Zealand is associated with *C. fetus* subsp. *fetus*. Campylovexin® (Schering-Plough Animal Health Ltd., Upper Hutt) is a single-strain, killed vaccine available in New Zealand for the prevention of abortion in sheep due to *C. fetus* subsp. *fetus*. The present study was initiated in response to questions regarding the protection offered by this vaccine against other strains of *C. fetus* subsp. *fetus* causing sheep abortion in New Zealand.

*Campylobacter* isolates from aborted sheep foetuses were collected after culture in veterinary diagnostic laboratories from sheep flocks in the Hawke’s Bay region in 1999. This was extended in 2000, when *Campylobacter* sheep abortion isolates cultured in the same way from farms throughout New Zealand were collected. In total, 374 *C. fetus* subsp. *fetus* isolates, 30 *C. jejuni* isolates, and one *C. coli* isolate were collected from 249 farms. These isolates were sub-typed using the genetic technique, pulsed-field gel electrophoresis (PFGE). A total of 26 distinct PFGE types were identified amongst the *C. fetus* subsp. *fetus* sheep abortion isolates, and one type, PFGE type B1, predominated. Of the farms from which *C. fetus* subsp. *fetus* was isolated, PFGE type B1 was found on 19 out of the 25 farms in the Hawke’s Bay study (75%) and 132 out of the 200 farms in the national study (66%).

Nine distinct PFGE types were found amongst the 30 *C. jejuni* isolates from the Hawke’s Bay and national studies. No single *C. jejuni* PFGE type was identified from sheep abortion most frequently. Investigation of a large sheep abortion outbreak initially attributed to *C. jejuni* revealed that the initial diagnosis was misleading due to contamination of the foetal sample, and that the outbreak was more likely to have been associated with *C. fetus* subsp. *fetus*.

Seven *C. fetus* subsp. *fetus* isolates representative of the genotypes found amongst New Zealand sheep abortion isolates in a 1987 study were lodged with the New Zealand Reference Culture Collection, Medical Section (de Lisle et al. 1987). These isolates were typed in the present study using PFGE, and were found to be similar or
indistinguishable from the PFGE types identified in the Hawke's Bay or national studies. The frequency of isolation of the types also appeared to be similar between 1987 and 2000, as the prevalent type from 1987 was identified as PFGE type B1.

A nationwide call for suspected cases of Campylovexin® breakdown resulted in the identification of one flock in which abortions due to C. fetus subsp. fetus were reported in ewes apparently vaccinated that season. Approximately 40 ewes aborted out of a flock of 1100 ewes, and it was thought that four ewes that had aborted were vaccinated that season. The high stocking density management of this flock meant that there was likely to have been a high challenge to vaccinated ewes from unvaccinated aborting ewes. Investigation of two other apparent Campylovexin® breakdown cases revealed that ewes had not been vaccinated that season and were also run at a high stocking density. In addition, the C. fetus subsp. fetus isolates in these two cases were the same PFGE type as the vaccine strain, PFGE type A1, which suggested that in these cases apparent vaccine breakdown was not due to lack of cross-protection against other strains. Despite the widespread occurrence of distinct strains of C. fetus subsp. fetus, abortion due to C. fetus subsp. fetus in ewes vaccinated with Campylovexin® appeared to be rare and was not associated with a particular PFGE type.

Serum from 15 ewes vaccinated with Campylovexin® was collected and used in Western blotting experiments to investigate antibody binding with the proteins of the various PFGE types of C. fetus subsp. fetus. Serum from vaccinated ewes contained antibodies that bound to the proteins of the different C. fetus subsp. fetus PFGE types. This in vitro study suggested that sheep vaccinated with Campylovexin® develop antibodies that recognise proteins of each of the C. fetus subsp. fetus strain types.

Vaccine challenge experiments were performed using pregnant guinea pigs as a model. Initially, it was shown using this model that Campylovexin® provided a statistically significant level of protection from homologous challenge with the vaccine strain. Then, using an isolate of PFGE type B1, it was demonstrated that Campylovexin® also provided a statistically significant level of protection against heterologous challenge.

Despite the range of C. fetus subsp. fetus PFGE types identified in this study, there was no evidence to suggest that the different strain types compromised Campylovexin®
efficacy in protection against *C. fetus* subsp. *fetus* sheep abortion. The protein recognition by serum from ewes vaccinated with Campylovexin®, the lack of a robust vaccine breakdown case, and the demonstration of cross-protection in the guinea pig model, provide evidence that Campylovexin® appears to offer cross-protection against strains of *C. fetus* subsp. *fetus* causing abortion in sheep in New Zealand.
Acknowledgements

I thank my team of supervisors:

Dr. Dave West  
Associate Professor  
Institute of Veterinary, Animal and Biomedical Sciences,  
Massey University, Palmerston North

Dr. Stan Fenwick  
Senior Lecturer in Veterinary Public Health  
School of Veterinary Clinical Science, Murdoch University,  
Perth, Australia

Dr. Roger Marchant  
Veterinary Adviser  
Schering-Plough Animal Health Limited, Upper Hutt

Dr. Kevin O’Connell  
Technical Manager R&D Global Vaccine Unit  
Schering-Plough Animal Health Limited, Upper Hutt

I thank Stan and Roger for dreaming up this project, constructing a plan and obtaining the funding from Technology New Zealand. I would like to thank them both for their support and especially Roger for his endless enthusiasm. Dave has been a fabulous strength in this project and I thank him for his support and for getting me to think.

Trudy Owen (Regulatory Affairs Manager, SPAH) has been an invaluable source of advice and support and provided useful input at the project meetings. I would also like to recognise the time and support of Marty Phillips (Division Manager, SPAH) towards this project.

I thank the friendly crowd at SPAH for making me feel welcome, particularly the staff of R&D, QA, and QC. I would especially like to thank Philip Wallace (Wally) and Jacquie Clarke for providing a home-away-from-home for me in the Hutt.

I thank Megan Leyland (PFGE Typing Laboratory technician, IVABS) for sharing her considerable PFGE expertise, including help with Diversity Database and with the production of endless dendrograms. I would like to thank the microbiology staff of the veterinary diagnostic laboratories who supplied Campylobacter abortion isolates. I thank Kylie Walker (MicroLab technician, IVABS) for storing the Campylobacter
isolates from the Hawke's Bay in 1999 and the staff at Veterinary Services Hawke's Bay Ltd. for their continued support of this project.

Thank you to the veterinarians who advised us of suspected breakthrough cases: Sonya Jackson (North Canterbury Veterinary Services) and Carolyn Hamill (Edendale Vet Club), and the farmers for their cooperation in this investigation.

I would like to thank IVABS veterinarians Drs. Anne Ridler, Mark Owen, Dave West, Alison Quinn, Alastair Johnston, Mark Collett, and especially Dr Kathy Parton (IVABS Laboratory Animal Veterinarian), for advice and assistance with guinea pig procedures of a veterinary nature. I thank Debbie Chesterfield (Small Animal Production Unit, Massey University) and Rob Hazelwood (SPAH Animal Breeding Unit) for advice and assistance. I would like to thank Dr Nigel Perkins (Epidemiologist, IVABS) for statistical advice and Dr Alan Murray for helpful suggestions. I thank Dr Anne Midwinter for assistance with the Petroff-Hausser counter and Mike Hogan (Post-mortem room technician, IVABS) for assistance.

Finally, but not least, I would like to thank my family and friends for their support, particularly Anne Ridler, Julie Thompson, and Rowena Taylor for reviewing thesis drafts.

This work was supported by a Technology New Zealand Technology for Industry Fellowship in conjunction with Schering-Plough Animal Health Ltd.
Table of Contents

Abstract ii
Acknowledgments v
Table of contents vii
List of figures x
List of tables xv
List of appendices xviii

Chapter 1: Literature review 1
1.1 Introduction 2
1.2 The genus Campylobacter 2
1.3 Identification of Campylobacter species 5
1.4 Epidemiology of Campylobacter abortion in sheep 14
1.5 Strain typing of Campylobacter sheep abortion isolates 25
1.6 Prevention of Campylobacter abortions in sheep 32
1.7 Surface layer proteins (SLPs) 36
1.8 Animal challenge models for C. fetus subsp. fetus vaccine efficacy 45
1.9 Objectives of the present study 48

Chapter 2: General Materials and Methods 50
2.1 Manufacturers’ addresses 51
2.2 Media, stains and solutions 52
2.3 Campylobacter growth and identification 55
2.4 Pulsed-field gel electrophoresis (PFGE) 59
2.5 SDS-polyacrylamide gel electrophoresis 61
2.6 Collection of serum from vaccinated ewes 62
2.7 Western blotting 63
Chapter 3: Typing of Campylobacter fetus subsp. fetus from sheep abortions using pulsed-field gel electrophoresis: a pilot study of Hawke’s Bay isolates

3.1 Introduction 66
3.2 Materials and methods 68
3.3 Results 70
3.4 Discussion 75
3.5 Conclusions 77

Chapter 4: Typing of Campylobacter fetus subsp. fetus sheep abortion isolates using pulsed-field gel electrophoresis: a New Zealand study

4.1 Introduction 79
4.2 Materials and methods 80
4.3 Results 83
4.4 Discussion 94
4.5 Conclusions 97

Chapter 5: Pulsed-field gel electrophoresis of Campylobacter jejuni sheep abortion isolates

5.1 Introduction 99
5.2 Materials and methods 101
5.3 Results 103
5.4 Discussion 110
5.5 Conclusions 115
| Chapter 6: *In vitro* protein and serological studies of *Campylobacter fetus* subsp. *fetus* strains |
|---|---|
| 6.1 Introduction | 116 |
| 6.2 Materials and methods | 117 |
| 6.3 Results | 118 |
| 6.4 Discussion | 123 |
| 6.5 Conclusions | 132 |

| Chapter 7: *Campylovexin*® breakdown investigation |
|---|---|
| 7.1 Introduction | 136 |
| 7.2 Materials and methods | 137 |
| 7.3 Results | 139 |
| 7.4 Discussion | 141 |
| 7.5 Conclusions | 147 |

| Chapter 8: *Campylovexin*® efficacy in the pregnant guinea pig model |
|---|---|
| 8.1 Introduction | 152 |
| 8.2 General Materials and Methods | 153 |
| 8.3 Determination of MAD50 for A1 and B1 | 155 |
| 8.4 Vaccine challenge experiments | 158 |
| 8.5 Conclusions | 177 |

| Chapter 9: General discussion |
|---|---|
| 9.1 Introduction | 191 |
| 9.2 Strain typing of *Campylobacter fetus* subsp. *fetus* | 192 |
| 9.3 *Campylobacter jejuni* | 194 |
| 9.4 *In vitro* protein and serological studies | 195 |
| 9.5 *Campylovexin*® breakdown investigation | 196 |
| 9.6 Investigation of *Campylovexin*® protection using an animal challenge model | 198 |
| 9.7 Summary | 199 |
List of Figures

Figure 1.1 Circular, white lesions on the foetal liver found in approximately one quarter of *Campylobacter fetus* subsp. *fetus* abortion cases. 16

Figure 2.1 *Campylobacter fetus* subsp. *fetus* colonies on a blood agar plate. 55

Figure 2.2 Gram stain of *C. fetus* subsp. *fetus*. 56

Figure 2.3 Pulsed-field gel electrophoresis tank. 60

Figure 2.4 Mini-Protean II electrophoresis system. 61

Figure 2.5 Western Blotting apparatus. 63

Figure 3.1 Pulsed-field gel electrophoresis (PFGE) using the restriction enzyme *Sma*I of the ten PFGE types isolated from sheep abortions in Hawke’s Bay in 1999, and the Campylovexin vaccine strain (A1). 71

Figure 3.2 Similarity of the PFGE profiles of the *C. fetus* subsp. *fetus* isolates from the Hawke’s Bay in 1999 and the Campylovexin® strain (PFGE type A1). 72

Figure 4.1 Map of New Zealand showing the districts the farms of the 2000 national study were categorised as belonging to. 81

Figure 4.2 Pulsed-field gel electrophoresis using the restriction enzyme *Sma*I of the 22 PFGE types found amongst the 293 *C. fetus* subsp. *fetus* isolates in 2000, and the *C. fetus* subsp. *fetus* Type strain, K2. 84
Figure 4.3 Similarity of the PFGE profiles of the *C. fetus* subsp. *fetus* isolates.

Figure 4.4 Pie charts showing the proportion of farms in each region from which the *Campylobacter fetus* subsp. *fetus* PFGE types were isolated, and from which *C. jejuni* or *C. coli* was isolated.

Figure 4.5 PFGE using the restriction enzyme *Sma*I of the *Campylobacter fetus* subsp. *fetus* REA types a-g from the New Zealand Reference Culture Collection.

Figure 5.1 Pulsed-field gel electrophoresis using the restriction enzyme *Kpn*I of the 12 PFGE types found amongst the 30 *C. jejuni* isolates from 25 farms in 1999 and 2000, the one *C. coli* isolate, and the *C. jejuni*, *C. coli*, and *C. fetus* subsp. *fetus* Type strains.

Figure 5.2 Similarity of the *Kpn*I PFGE profiles of the *C. jejuni* and *C. coli* isolates.

Figure 5.3 Similarity of the *Sma*I PFGE profiles of the *C. jejuni* and *C. coli* isolates.

Figure 5.4 Pulsed-field gel electrophoresis using the restriction enzyme *Sma*I of the *C. coli* isolate; the *C. jejuni*, *C. coli*, and *C. fetus* subsp. *fetus* Type strains; and the 12 PFGE types found amongst the 30 *C. jejuni* isolates from 25 farms in 1999 and 2000.

Figure 6.1 Western blot showing antibody binding to the proteins of the Campylovexin® vaccine strain (5915) of pre-immune (p) and immune (i) serum from 11 individual ewes vaccinated with Campylovexin®.

Figure 6.2 Coomassie-stained SDS-PAGE gels of continuously subcultured isolates A1, A5, B1, B4, C1 and D1.
Figure 6.3 PFGE analysis of continuously subcultured isolates using the restriction enzyme Smal.

Figure 6.4 SDS-PAGE and Western blotting of PFGE types A1-A7 and F1-F5.

Figure 6.5 SDS-PAGE and Western blotting of PFGE types B1-B6 and C1-C2.

Figure 6.6 SDS-PAGE and Western blotting of PFGE types D1-D3, E1, E2, G1, H1, I1, J1, K1 and K2.

Figure 7.1 Pulsed-field gel electrophoresis using the restriction enzyme Smal of the C. fetus subsp. fetus isolates from Cases 1-3 from 2001 and the isolates from the 1996 Manawatu case.

Figure 7.2 Protein profile and serological analysis of the isolates from Cases 1-3 from 2001 and the isolates from the 1996 Manawatu case.

Figure 8.1 Guinea pig cage, showing feed hoppers and drink bottles, tunnels, plastic floor with drainage holes and drip trays.

Figure 8.2 Guinea pig weighing.

Figure 8.3 Difference in the daily weight of 25 guinea pigs for 36 consecutive days.

Figure 8.4 Timeline for both the A1 and B1 MAD50 determination experiments.

Figure 8.5 Timeline for both the A1 and B1 vaccine challenge experiments.
Figure 8.6 Ultrasound scanning of guinea pigs to detect pregnancy using a Linear Array 5-10 probe with the Ultramark 9 Ultrasound System.

Figure 8.7 Ultrasound photographs of guinea pig foetuses and placentae after 3-5 weeks gestation.

Figure 8.8 Necropsy of an aborting guinea pig.

Figure 8.9 Haemorrhagic uteri from aborting guinea pigs in the 5th-6th week of gestation.

Figure 8.10 Guinea pig uteri. A: uterus from a pregnant guinea pig, in the 7th-8th week of gestation, 21 days after challenge. B: uterus from a non-pregnant guinea pig.

Figure 8.11 Summary of guinea pig abortion data in the experiment to determine the MAD50 for A1.

Figure 8.12 Proportion of guinea pigs (GP) that aborted plotted against log10 inoculum dose in the experiment to determine the minimum dose at which half of the unvaccinated guinea pigs abort (Minimum Abortive Dose50, MAD50) for vaccine strain 5915 (PFGE type A1).

Figure 8.13 Summary of guinea pig abortion data in the experiment to determine the MAD50 for B1.

Figure 8.14 Proportion of guinea pigs (GP) that aborted plotted against log10 inoculum dose in the experiment to determine the minimum dose at which half of the unvaccinated guinea pigs abort (Minimum Abortive Dose50, MAD50) for PFGE type B1.
Figure 8.15  Proportion of guinea pigs (GP) that aborted plotted against log_{10} inoculum dose in the experiment to determine the minimum dose at which half of the unvaccinated guinea pigs abort (Minimum Abortive Dose_{50}, MAD_{50}) for PFGE type B1, showing the 95% confidence intervals (blue lines).

Figure 8.16  Summary of guinea pig abortion data in the vaccine challenge experiment with A1.

Figure 8.17  Summary of guinea pig abortion data in the vaccine challenge experiment with B1.

Figure 8.18  Protein profile and Western blotting of the challenge inocula in the MAD_{50} determination and vaccine challenge experiments, for both PFGE types A1 (isolate 5915) and B1 (isolate NS41).
List of Tables

Table 1.1 Nomenclature of *Campylobacter fetus*.  
Table 1.2 Serotypes, biotypes and group names assigned to *Campylobacter* spp.  
Table 1.3 Phenotypic tests of selected *Campylobacter* species.  
Table 1.4 Number of sheep abortion submissions and number of diagnoses of *C. fetus* subsp. *fetus*, other *Campylobacter* species and *Toxoplasma gondii*, for the years 1995-2001.  
Table 1.5 Interpretation of PFGE profiles.  
Table 3.1 Number of *C. fetus* subsp. *fetus* isolates of each PFGE type and number of farms from which each of the PFGE types was isolated.  
Table 4.1 Number of *C. fetus* subsp. *fetus* isolates of each PFGE type and number of farms from which each of the PFGE types was isolated in 2000.  
Table 4.2 Number of farms in each region from which the various PFGE types of *Campylobacter fetus* subsp. *fetus* were isolated in 2000.  
Table 4.3 Comparison of number of farms in the Hawke’s Bay in 1999 and 2000 from which each *C. fetus* subsp. *fetus* PFGE type was found.  
Table 4.4 Pulsed-field gel electrophoresis typing results of the REA types a-g from the New Zealand Reference Culture Collection and the number of farms in 1987 and 2000 from which the types were isolated.
Table 5.1  Number of isolates of each *Campylobacter jejuni* and *C. coli* PFGE type and number and location of farms from which these were isolated in 1999 and 2000.  

Table 5.2  Number of New Zealand sheep abortion cases of *C. fetus* subsp. *fetus* and other *Campylobacter* species for the years 1995-2001.  

Table 6.1  The isolate name, PFGE type and approximate size of the SLP initially expressed of the six isolates selected for continuous sub-culture.  

Table 6.2  Summary of SLP expression.  

Table 8.1  The challenge doses for both PFGE type A1 and B1 MAD$_{50}$ determination experiments, as calculated by the Petroff-Hausser method and by dilution plating.  

Table 8.2  Proportion of guinea pigs (GP) that aborted after each challenge dose in the experiment to determine the minimum dose at which half of the unvaccinated guinea pigs abort (Minimum Abortive Dose$_{50}$, MAD$_{50}$) for vaccine strain 5915 (PFGE type A1).  

Table 8.3  Number of challenged guinea pigs (GP) in each MAD$_{50}$ determination experiment that were culture positive for *C. fetus* subsp. *fetus*.  

Table 8.4  Proportion of guinea pigs (GP) that aborted after each challenge dose in the experiment to determine the minimum dose at which half of the unvaccinated guinea pigs abort (Minimum Abortive Dose$_{50}$, MAD$_{50}$) for PFGE type B1.  

Table 8.5  The challenge doses for both PFGE type A1 and B1 vaccine challenge experiments, as calculated by the Petroff-Hausser method and by dilution plating.
Table 8.6 Numbers of vaccinated and unvaccinated guinea pigs that were mated, were found to be pregnant and challenged, and subsequently aborted in the vaccine challenge experiment with $100\times\text{MAD}_{50}$ A1.

Table 8.7 Numbers of vaccinated and unvaccinated guinea pigs that were mated, were found to be pregnant and challenged, and subsequently aborted in the vaccine challenge experiment with $100\times\text{MAD}_{50}$ B1.
List of Appendices

Appendix 1  Similarity matrix of *Campylobacter fetus* subsp. *fetus* PFGE types from Hawke’s Bay in 1999. 200

Appendix 2  Pulsed-field gel electrophoresis data for the isolates from the Hawke’s Bay 1999 study. 201

Appendix 3  Similarity matrix of all *Campylobacter fetus* subsp. *fetus* PFGE types identified to date. 203

Appendix 4  Pulsed-field gel electrophoresis data for the isolates from the 2000 national study. 205

Appendix 5  Similarity matrix of *Campylobacter jejuni* PFGE types – *KpnI*. 212

Appendix 6  Similarity matrix of *Campylobacter jejuni* PFGE types – *SmaI*. 213

Appendix 7  National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) protein-protein search results of sequence: MISKSE in positions 1-6. 214